What is the study drug (KD025)?

The study drug is an investigational tablet designed to target the ROCK2 pathway. Pathways are how cells in the body communicate with each other to help our bodies function. When ROCK2 is overactivated, it may result in inflammation of the skin and damage to internal organs. One goal of the study is to see if targeting ROCK2 can help with the symptoms of scleroderma. 

What is an investigational drug?

Investigational drugs are not approved for public use by regulatory authorities, such as the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These drugs cannot be sold in stores or prescribed by doctors. They can only be used for research purposes.

Have other people used KD025 before?

Yes. Previous clinical studies have researched the safety and effectiveness of the study drug for other conditions that may also be caused by a malfunctioning ROCK2 pathway. Findings from these studies suggest that targeting ROCK2 may reduce inflammation in conditions like scleroderma.